ClinicalTrials.gg
RecruitingNCT06649331Updated Sep 3, 2026

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

A Phase 2 interventional study of SHR-A1811 and SHR-A1921 in Advanced Breast Cancer, Metastatic Breast Cancer and Triple Negative Breast Cancer (TNBC), sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know · 17 judgments

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Triple Negative Breast Neoplasms by Fudan University — 35 open to participants now, 39 under way, 12 of them phase 3. Triple Negative Breast Neoplasms · Fudan University.

Planned enrollment
20th of 62
160 · median 110
Started
2024
with 7 others
Phase 2
41 of 65
20 open now
Primary completion
2026-09
later than 15 of 38 live
Registered
49th of 65
by date

Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, this one is the 20th largest by planned enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2024, is one of 41 in phase 2, reaches primary completion later than 15 of the 38 other live ones, and was the 49th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 65 studies in Triple Negative Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

Where they have run

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Triple Negative Breast Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.

Read the detailed description

This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously received ADCs.

The primary endpoint is objective response rate (ORR). This trial aims to learn whether ADC rechallenge works in treating in ADC-treated metastatic breast cancer and identify which ADC works better for subsets on the basis of molecular characteristics and ADC treatment history of their disease with high ORR. Study drugs involved in this study including but not limited to: SHR-A1811 (HER2 ADC), SHR-A1921 (TROP2 ADC), SHR-A2009 (HER3 ADC) and SHR-A2102 (Nectin-4 ADC).

This platform trial is adaptive design. Novel ADC regimens with sufficiently high activities that show a high Bayesian predictive probability will graduate from the trial with their corresponding biomarker signature(s). ADCs will be dropped if they show a low probability of improved efficacy with any biomarker signature. New ADCs will enter as those that have undergone testing complete their evaluation.

Based on the existing four ADC treatment cohorts on this platform, a maximum of 120 subjects were planned to be enrolled in each ADC treatment cohort. According to the previous ADC treatment history and target, the subjects were randomly assigned to each cohort. On the basis of previous clinical data at our center, we limited the enrollment of a minimum of 10 participants per cohort to avoid underrepresentation of any cohort. During the course of the study, ORR will be evaluated periodically for every additional 10 results according to the Bayesian monitoring method. Graduation (successful validation) or elimination (failed validation) of ADC rechallenge treatment will be considered according to the posterior probability of an ADC cohort and the data of primary efficacy endpoint, secondary efficacy endpoints and safety endpoints. Additional targeted regimens may be added to the platform regimen as feasible as assessed by the investigators, and the protocol will be modified accordingly at that time.

The efficacy was evaluated by CT or MRI every 6 weeks (±1 week) according to RECIST 1.1. Subjects with CR or PR were required to have radiologic response confirmation at least 4 weeks. Tumor assessments were performed every 9 weeks (±1 week) after 36 weeks of treatment until disease progression, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, death, or the end of the study, whichever occurred first.

03

Conditions studied

  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Triple Negative Breast Cancer (TNBC)
  • HER2-negative Breast Cancer
  • Breast Cancer

Browse trials for

Keywords

  • platform trial
  • adaptive design
  • antibody-conjugated drugs (ADCs)
  • Bayesian predictive probability
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 160 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent breast cancer;
  3. Previously received ADCs;
  4. The most recent pathology results will be considered for enrollment according to local testing of ER, PR and . Participants with any hormone receptor (HR) status will be allowed on study.
  5. Prior endocrine therapy: Participants with HR-positive breast cancer must have received prior CDK4/6 inhibitor;
  6. Participants must have per 1.1.
  7. The functions of the main organs are basically normal and meet the following conditions:

    I. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood transfusion within 14 days); The ANC acuity 1.5 x 10\^9 / L; acuity 75 x 10\^9 / L; II. Biochemical tests should meet the following criteria: ≤1.5× (upper limit of normal value); and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1.5×ULN, endogenous > 50 ml/min (Cockcroft-Gault formula); III. ≥50%

  8. They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity; Participants may have discontinued all CDK4/6 inhibitor at least 14 days prior to study treatment initiation. Prior endocrine therapy does not require washout.
  9. score ≤2, and ≥3 months;
  10. Fertile female subjects were required to use a medically approved method during the study treatment period and for at least 3 months after the last use of the study drug;
  11. Subjects volunteered to join the study, signed , had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone );
  2. Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with or mannitol);
  3. A history of or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months;
  4. Presence of the third space effusion (such as massive ascites, pleural effusion, pericardial effusion) that cannot be controlled by drainage or other methods;
  5. Participants with who had used agents or systemic corticosteroids within 2 weeks before the first dose (dose> 10mg/day prednisone or other corticosteroids at the physiological dose of the drug), excluding nasal spray or inhaled corticosteroids;
  6. Presence of any active disease or a history of autoimmune disease with potential relapse;
  7. Known (HIV) infection that is not well controlled;
  8. Known active (HBV DNA≥2000 IU/mL or 104 copies/mL) and (positive for hepatitis C antibodies and HCV-RNA above the lower detection limit of the assay);
  9. Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes;
  10. Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment;
  11. Pregnant or lactating patients;
  12. (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years;
  13. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent or accompanying supportive medications;
  14. Serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study or interfere with the study results
  15. Deemed by the investigator to be ineligible for participation in the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    A

    SHR-A1811 (HER2 ADC)

    Drug: SHR-A1811

  • Experimental
    B

    SHR-A1921 (TROP2 ADC)

    Drug: SHR-A1921

  • Experimental
    C

    SHR-A2009 (HER3 ADC)

    Drug: SHR-A2009

  • Experimental
    D

    SHR-A2102 (Nectin4 ADC)

    Drug: SHR-A2102

  • Experimental
    E

    SHR-A1811 (HER2 ADC) and Famitinib (VEGFR inhibitor)

    Drug: SHR-A1811 · Drug: Famitinib

  • Experimental
    F

    SHR-A1811 (HER2 ADC) and Fat Module Formula for Special Medical Purposes (for Medium-Chain Triglyceride Supplementation)

    Drug: SHR-A1811 · Dietary Supplement: Fat Module Formula for Special Medical Purposes

  • Experimental
    G

    9MW2821 (Nectin4 ADC)

    Drug: 9MW2821

  • Experimental
    H

    9MW2821 (Nectin4 ADC) + trastuzumab

    Drug: Trastuzumab (or biosimilar) · Drug: 9MW2821

  • Experimental
    I

    Disitamab Vedotin (RC48)

    Drug: Disitamab Vedotin (RC48)

  • Experimental
    J

    Treatment of physician's choice (TPC)

    Drug: Treatment of physician's choice (TPC)

Interventions

  • DrugTrastuzumab rezetecanStudies of Trastuzumab rezetecanTrastuzumab rezetecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

  • DrugTizetatug rezetecanStudies of Tizetatug rezetecanTizetatug rezetecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.

  • DrugRuzaltatug rezetecanStudies of Ruzaltatug rezetecanRuzaltatug rezetecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.

  • DrugNotiretatug rezetecanStudies of Notiretatug rezetecanNotiretatug rezetecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.

  • A VEGFR inhibitor administered orally per the protocol.

  • Dietary supplementFat Module Formula for Special Medical Purposes

    This nutritional formulation is composed primarily of medium-chain triglycerides (MCT), which are metabolized by the liver to induce nutritional ketosis, thereby significantly elevating circulating levels of beta-hydroxybutyrate (BHB).

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    An anti-HER2 antibody, via intravenous (into the vein) infusion or subcutaneous per protocol.

  • DrugBulumtatug fuvedotinStudies of Bulumtatug fuvedotinBulumtatug fuvedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.

  • DrugDisitamab vedotinStudies of Disitamab vedotinDisitamab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

  • DrugTreatment of physician's choice (TPC)

    Treatment of physician's choice (TPC), such as nab-paclitaxel, carboplatin, gemcitabine, capecitabine, vinorelbine, eribulin, etc., with specific dosages and administration methods determined at the investigator's discretion.

07

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR), defined as best overall response of either complete or partial response, will be assessed among participants who start protocol therapy and have measurable disease at screening. Radiographic response will be assessed using RECIST 1.1 criteria as defined per protocol.

    Time frame: The observation period related to this endpoint is up to 36 months.

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS based on Kaplan-Meier methodology will be defined as the time from randomization until the identification of disease progression or death, whichever occurs first. Subjects without disease progression or death at the time of analysis will be censored at the date of last disease evaluation.

    Time frame: The observation period related to this endpoint is up to 36 months.

  2. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the proportion of participants with CR, PR and stable disease (SD) for ≥ 4 weeks as the best overall response.

    Time frame: The observation period related to this endpoint is up to 36 months.

  3. Clinical Benefit Rate (CBR)

    Clinical Benefit Rate (CBR) is defined as the proportion of participants with CR, PR and stable disease (SD) for ≥ 24 weeks as the best overall response.

    Time frame: The observation period related to this endpoint is up to 36 months.

  4. Duration of Response (DOR)

    The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started, or death due to any cause). Participants without reported events are censored at the last disease evaluation.

    Time frame: The observation period related to this endpoint is up to 36 months.

  5. Overall Survival (OS)

    Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.

    Time frame: The observation period related to this endpoint is up to 5 years.

  6. Treatment-Related Toxicity Rate

    The percentage of participants who experienced any grade treatment-related adverse event based on the Common Toxicity Criteria for Adverse events Version 5.0 (CTCAEv5) as reported on case report forms.

    Time frame: The observation period related to this endpoint is up to 36 months.

Other outcomes

  1. Exploration of translational research markers

    The collected subjects' tumor tissues, paracancerous tissues, blood, and fecal samples will be used for discovering exploratory biomarkers (including but not limited to the expression of HER2, TROP2, HER3, Nectin4, etc.). The relationships between discovered biomarkers and subjects' disease status and treatment responses will also be investigated.

    Time frame: The observation period related to this endpoint is up to 36 months.

08

Study locations

1 of 1 sites recruiting
  • Breast cancer institute of Fudan University Cancer Hospital
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Zhimin Shao, M.D · Contactzhimingshao@yahoo.com · 86-21-64175590
    • Xiyu Liu, M.D. · Sub investigator
    • Lei Fan, M.D. · Sub investigator
    • Zhimin Shao, M.D. · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2026, 23 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 23 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Oct 21, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06649331
Lead sponsor
Fudan University
Responsible party
Zhimin Shao (Professor, Fudan University) — Principal investigator
First posted
Oct 18, 2024
Start date
Oct 21, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Zhimin Shao, M.D.
Contact
Zhimingshao@yahoo.com
86-21-64175590
Xiyu Liu, M.D.
Contact
10301010079@fudan.edu.cn
86-21-64175590
Zhimin Shao, M.D.
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Tizetatug rezetecan · Ruzaltatug rezetecan · Notiretatug rezetecan · Famitinib · Bulumtatug fuvedotin · Disitamab vedotin

Start the discussion